Drug ads shifted AI treatment recommendations in controlled tests, even when answers remained clinically reasonable.
Accuracy alone can miss commercial influence.
Three checks for pharma leaders investing in AI visibility:
disrupting.healthcare/2026/1…
5
The UK cut measured trial set-up to 112 days, yet industry recruitment fell again. Pelacarsen lowered Lp(a) 78% without reducing major CV events. Different stories, same trap: a milestone is not an outcome. Weekly Signal #62.
disrupting.healthcare/2026/1…
10
Q3 Europe growth: AZ +12%, Novartis +3%, GSK +3%, Sanofi −0.9% at constant currency. Inside those totals sit launches, expansion, erosion and shipment timing. Signal #61 asks how each portfolio opportunity should be funded for 2027.
disrupting.healthcare/2026/1…
20
ESMO puts treatment timing into the oncology forecast. Weekly Signal #60 looks at Moderna’s personalised melanoma vaccine, the debate over care before surgery, and Amgen’s separate maintenance result.
disrupting.healthcare/2026/1…
Rasonque’s phased EMA review puts evidence timing into the launch investment plan. JCA deadlines link to regulatory milestones; national access follows its own route. Which commitments move earlier?
Weekly Signal #59: disrupting.healthcare/2026/1…
8
The EU pharma package would make the standard tenth protection year conditional. Different qualifying routes require different investments; each asset needs its own valuation. Weekly Signal #57 asks which route is worth funding. disrupting.healthcare
4
The nine new US MFN agreements are not one price formula. They bundle Medicaid access, future launch pricing, US manufacturing and tariff relief into company-specific bargains.
MFN is no longer a market-access workstream. It is an enterprise deal.
disrupting.healthcare/2026/0…
Your protocol stays fixed. Its comparator does not.
Standards of care shift. Price anchors move. Supply fails. AI changes the operating baseline.
Five signals. One management problem: who owns the gap when the benchmark moves?
disrupting.healthcare/2026/0…
One factory. Two filings. The US dossier had a second site named. Europe did not. The US clock held. Europe restarted.
Time-to-market is not a launch metric. It is an upstream design choice.
Weekly Signal #51: The Price of Time-to-Market
disrupting.healthcare/2026/0…
Approval opens the door. Access depends on others.
Swiss pricing, Lilly’s UK obesity pill, Europe’s Lyme vaccine review and Abbott and Google show who really controls the route to market.
Weekly Signal #50: disrupting.healthcare/2026/0…
12
Markets don’t price an operating model as a line item. They price what it produces or discount the friction when it fails.
Weekly Signal #49 connects BioNTech, Integer, Proscia, Merck, Smith+Nephew, and Oxford Biomedica.
The Operating Model Gets Priced:
disrupting.healthcare/2026/0…
20
Weekly Signal #48: The Reallocation Quarter
Sanofi cut three programmes. GSK is shifting £1.9bn into 20+ Phase III starts. Novo hit the biomarker, not the outcome. MedTech margins got help from tariff refunds.
Strategy shows in where capacity moves. disrupting.healthcare/2026/0…
31
The molecule earns attention. The route earns scale.
Samsung–PolyPeptide, Roche’s formulation conversion, Dassault–ArisGlobal, Sanofi’s amlitelimab stop, July CHMP all point to the same: owning what's between scientific possibility and patient adoption.
disrupting.healthcare
1
42
Europe Life Sciences Weekly Signal #47: The Route Is the Strategy - disrupting.healthcare
1
A molecule, an AI platform, a US rare-disease infrastructure play, and Europe’s regulatory machinery all pointed in one direction this week: the advantage is no longer owning every input. It is owning the system that makes those inputs worth more.
disrupting.healthcare/2026/0…
1
European digital health: access is not adoption.
A CE mark, DiGA listing or PECAN decision gets you to the starting line.
The IP gets you noticed. The operating model gets you renewed.
disrupting.healthcare/2026/0…
6
The EU AI Act deadline moved. The operating-model question didn't.
Life sciences commercial teams should use the extra runway to inventory AI across CRM, patient support, field-force analytics, content and market access.
disrupting.healthcare/2026/0…
9
European MedTech launches rarely fail because the product is weak.
They fail because the commercial model is still built for clinician-led adoption, whereas Europe now buys based on procurement, reimbursement, evidence, and budget logic.
New piece: disrupting.healthcare/2026/0…
Quiet week in life sciences. Loud signal.
GSK: oral carbapenem.
Roche: subcut lymphoma regimen for community care.
Germany: drug pricing is trade policy.
Novo: oral GLP-1 race.
The molecule earns approval.
The delivery model earns the market.
disrupting.healthcare/2026/0…
New AI-guided MDR platform from HTH Copenhagen.
Most interesting founder insight: startups didn’t mainly get stuck on regulation. They got stuck defining intended use, clinical claims and target users.
The bottleneck was upstream of MDR.
disrupting.healthcare/2026/0…
